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Additional Professor, Department of Cardiology, All India Institute of Medical Sciences, Delhi, IndiaIndian pharmaceutical industry is successfully following the
‘make in India’ theme, much before it became a buzz word in
governance. India has dominated themanufacturing of generic
and bio-similar drugs. A few of the Indian companies have
made anti-tubercular, anti-retroviral and anti-cancer drugs
available to the vast majority of the world population at a
fractionof thecostof theirpatentedcounterparts.Make in India
theme has helped the Indian pharmaceutical industry to forge
ahead even in difficult economic times clocking an annual
growth of >10% for over a decade. It may appear fragmented
with around 24,000 estimated players; but it has around 350
companies in the organized sector and nearly one third of the
market is dominated by the top ten companies. In terms of
volumes, Indian pharmaceutical industry is the third largest in
theworld.However, Indianshare is ameager1e2%of theglobal
market share and is ranked a distant 10th in terms of value.1
India entered the global scene mainly through its engineered
generic drugs and active pharmaceutical ingredients. For
instance, India has 74 US FDA-approved manufacturing units,
highest in any country outside the US.2 Indian industries
presence in the patented drugs club is nearly non-existent.
After success in the generic market and it (generic market)
getting competitive and highly regulated, a few Indian phar-
maceutical companies have ventured into the field of new
molecule development and have accordingly increased their
research and development expenses. Most of the efforts have
gone into making innovative processing for existing mole-
cules, making different combination and/or formulations of
existing drugs and making bio-similar agents. Some of the
most successful combinations that have crossed Indian
boundaries include the various poly-pills developed by Indian
industries.3,4 However, as of date, only a very few new mole-
cules have been developed in India (one of them is the newer
anti-malarial e Synriam).5 In this context, saroglitazar, a* Corresponding author. Department of Cardiology, Room No. 10, 8th
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a/g agonist, is a novel first in class drug and is the first indig-
enously developed new clinical entity by any Indian phar-
maceutical company, ever!6
In this issueof Indianheart journal, Shetty SRet al.,7 describe
the encouraging results of a post marketing surveillance report
on the safety and efficacy of saroglitazar in Indian diabetic
dyslipidemia patients. Saroglitazar is a dual PPAR-a/g agonist,
with predominant PPARa and moderate PPARg activity.8 The
mechanism of action and the resultant effects are summarized
in the Fig. 1. PPAR are transcription factors; a group of nuclear
receptor proteins that regulate the expression of various genes.
PPAR have been shown to play a key role in a wide variety of
cellular events including cellular development and differentia-
tion, carbohydrate, lipid and protein metabolism, and tumori-
genesis. Currently, 3 types of PPARs have been identified: alpha,
gamma, and delta (beta). PPAR-alpha is expressed in liver, kid-
ney, heart, muscle, and adipose tissue. PPAR-alpha is a key
regulator of hepatic lipid metabolism. PPAR-alpha promotes
fatty acid utilization. In energy deprivation, PPAR-alpha is acti-
vated that stimulates ketogenesis. PPAR b/d is markedly
expressed inbrain and also in adipose tissue, and skin. PPARg is
expressed in three forms: g1e expressed in virtually all tissues,
g2e expressedmainly inadipose tissueandg3. PPARGregulates
glucose metabolism and storage of fatty acid.9 A few existing
molecules are PPAR agonists; fibrates activate PPARa, and the
anti diabetic thiazolidinediones activate PPARg. Combined
activation of PPAR a and gwould result in anti diabetic and anti-
dyslipidemic effects. For instance, the antidiabetic properties of
pomegranate flower are suggested to be due to dual PPAR-
alpha/-gamma activator properties.10 Saroglitazar is another
novel dual PPAR-alpha/-gamma activator.
In the limited literature available, saroglitazar has shown
goodefficacyandacceptablesafetyprofile.6e8 In thedoubleblindFloor, All India Institute of Medical Sciences, New Delhi 110029,
reserved.
Fig. 1 e Mechanism of action of saroglitazar.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 8e1 0 9PRESS V and Press VI studies,11,12 saroglitazar has demonstrated
excellent anti-glycemic and anti-lipid effects in patients with
diabetic dyslipidemia as compared to placebo or Pioglitazone.
Based on these evidences, saroglitazar is approved for clinical
use in India. In this issue of IHJ, data on the post marketing
surveillance of the use of saroglitazar 4 mg in 3133 diabetic
dyslipidemic patients over a 3 months period is presented.7
There was 35.8% reduction in triglycerides, 16.4% reduction in
LDL cholesterol, 19% reduction in total cholesterol and 23.4%
reduction in non-HDL cholesterol. In addition, the use of sar-
oglitazar showed an impressive 0.9% absolute reduction in
HbA1c. Unlike the fibrates and niacin, the drug is well tolerated.
No serious adverse events including edema andweight gain are
reported; two common side effects known to occur with drugs
havingasimilarmechanismofaction.Thebetter tolerabilityand
absence of significant side effects could be due to the absence of
thiazolidinedione (TZD) ring in saroglitazar molecule.
The data presented is of post marking surveillance. Lack of
consistent inclusion criteria and the differing data quality are
the major drawbacks of such a survey. Under-reporting of
complications and inadequate denominator data (i.e., number
of persons received the drug) are the other shortcomings of
such post marking surveillance. However, combined with
previous clinical trials, the data arguers well for the routine
use of saroglitazar in diabetic dyslipidemia not controlled
with statin. However, further development and global launch
of saroglitazarmolecule is challenging for a variety of reasons.Definitely the sponsor need to organize a large multi-centric,
randomized controlled trial (RCT) with FDA monitoring
using clinically meaningful hard end points. Majority of
similar agents in the field of lipidology have failed to prove
their absolute need over and above good doses of statins,
including fibrates and niacin.13,14 Even though it is known that
low HDL and high TG are risk factors for CVD, there is no
proven therapy that reverses these risks and produces clinical
benefit.15 In the field of anti-diabetic medication also cardio-
vascular risk reduction is rarely shown in a clinical trial.
Organizing mega multicentric trials are extremely expensive
and are risky. New molecule development is also time
consuming; saroglitazar was also discovered in 2001, but was
approved for the treatment of Type II diabetes by the Drug
Controller General of India only in June 2013. A failed RCT
could create havoc for the finances of the company, but a
positive trial could truly create the first ‘Indian global mole-
cule’ and a true Indian multinational pharmaceutical com-
pany. Only then it can claim the status of ‘made in India’.r e f e r e n c e s
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